Objective:To investigate the curative effect of autologous peripheral blood stem cell transplantation（APBSCT）in the treatment of malignant lymphoma. Methods:Ninety-nine cases of malignant lymphoma patients were admitted and treated with APBSCT in the hematology department of our hospital from 2005 to 2015. Results:（1）Of the 99 cases

11 were Hodgkin’s lymphoma

88 with non-Hodgkin’s lymphoma（60 cases of B-cell and 28 cases of T/NK-cell）

with a median age of 44（16 to 69）years old. Ratio of male to female was 68 ∶31. The patients with international prognostic index（IPI）scores≤2 were 78 cases while 21 cases with IPI scores>2. According to the stages of lymphoma

84 cases were stage Ⅲ/Ⅳ. Before APBSCT

65 patients were in complete remission（CR）. Among all the 60 patients with B-cell non-Hodgkin’s lymphoma

31 cases were treated in combination of Rituximab

while another 29 patients without the addition of Rituximab.（2）Enough peripheral blood hemopoietic stem cell were collected from the patients who accepted APBSCT after the mobilization. All the patients achieved hematopoietic reconstitution after transplantation

excepted two patients

who died because of septicopyemia. The overall survival rate（OS）of 3-years and progression-free survival rate（PFS）were 74.70% and 61.60%. The 3-year OS and PFS rate in the patients

who achieved CR before transplantation were 86.20% and 76.90%

while 52.90% and 32.40% in the patients with non CR status. The OS and PFS rate of the two groups had significant statistical differences（P =0.000

P =0.000）. The 3-year PFS rate in the group with IPI scores ≤2 were 69.20% and in the group with IPI scores>2 were 33.30% and had statistically significant differences（P=0.000）. The 3-year PFS of the patients with B-cell non-Hodgkin’s lymphoma and T-cell non-Hodgkin’s lymphoma had significant statistical differences（3-year PFS were 70.00% vs. 42.90%

P=0.019）. The 3-year OS and PFS of the patients who treated in combination of Rituximab and chemotherapy had no statistical difference with the patients who treated without Rituximab（P=0.152

P=0.368）. Conclusion:APBSCT is a safe and effective method for the treatment of malignant lymphoma. T-cell non-Hodgkin’s lymphoma

non CR status and IPI scores>2 before APBSCT are the independent adverse prognostic factors for lymphoma.